Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
Phase 2
86
about 6.5 years
18+
1 site in UT
About this study
Researchers are testing whether nicotinamide helps prevent new non-melanoma skin cancers (NMSC) in people with chronic lymphocytic leukemia (CLL). Participants will take either nicotinamide or a placebo for two years. The trial will stop if there's no difference between the groups, meaning that nicotinamide doesn't help prevent NMSCs.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Nicotinamide
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
nicotinamide
Secondary: frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0 and iwCLL), seriousness, duration, and relationship to study treatment, objective response rate (the proportion of subjects achieving a CR or PR) and complete response rate as calculated per International Workshop on CLL (IWCLL) 2018 Criteria at Month 6, 12, 18, and 24, objective response rate (the proportion of subjects achieving a complete response [CR] or partial response [PR]) and complete response rate as calculated per International Workshop on CLL (IWCLL) 2018 Criteria at Month 6, 12, 18, and 24
Oncology